Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Colorectal Cancer

 

Capecitabine and Celecoxib w/wo Radiation Therapy for Colorectal Cancer Patients Previously Treated With Fluorouracil (ADAPT - 7707)
A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer

Investigator: Edward Lin, MD;   Conditions: Colon Cancer, Rectal Cancer;    Status: Recruiting;   Study ID: NCT01729923

TheraSphere® Metastatic Colorectal Carcinoma of the Liver (7627 - TS-102)
A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy

Investigator: William Harris;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01483027

MDX-1105 for Advanced or Recurrent Cancer (UW08038)
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors

Investigator: Scott S. Tykodi, MD, PhD;   Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer;    Status: Closed;   Study ID: NCT00729664

Chemotherapy or Chemotherapy + Radiation for Rectal Cancer Patients Undergoing Surgery (The PROSPECT Trial-N1048)
A Phase II/III Trial of Neoadjuvant FOLFOX, With Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection With Total Mesorectal Excision

Investigator: Gabriela Chiorean, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01515787

FOLFOXIRI/Avastin Versus FOLFOX/Avastin for Metastatic Colorectal Cancer-STEAM (13010)
STEAM: (Sequential Triplet And Avastin Maintenance): Folfoxiri/Bevacizumab Regimens (Concurrent And Sequential) Vs. Folfox/Bevacizumab In First-Line Metastatic Colorectal Cancer

Investigator: Gabriela Chiorean, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01765582

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

Xilonix in Patients With Advanced Colorectal Cancer
Phase III Double-blinded, Placebo Controlled Study of Xilonix™ (MABp1) for Improving Survival in Metastatic Colorectal Cancer

Investigator: Andrew L. Coveler, MD;   Conditions: Metastatic Colorectal Cancer;    Status: Pending;   Study ID: NCT01767857

Regorafenib Versus Placebo Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases (20131931)
A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

Investigator: Edward Lin, MD;   Conditions: Colon Cancer, Rectal Cancer;    Status: Recruiting;   Study ID: NCT01939223

FOLFOX w/wo Celecoxib for Resected Stage III Colon Cancer (CALGB 80702)
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer

Investigator: Saul E. Rivkin, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT01150045

Irinotecan + Cetuximab w, w/o Vemurafenib for Colorectal Cancer (SWOG 1406)
Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer

Investigator: Andrew L. Coveler, MD;   Conditions: Colorectal Cancer;    Status: Recruiting;   Study ID: NCT02164916